Acetylcysteine

Cannabis use disorder (CUD) affects 14.2 million Americans, with 9% of users developing CUD, rising to 17% for adolescent starters and 30% for daily users. Adolescent drug use dropped in 2024, but high-potency cannabis products increase CUD risk. CUD symptoms include impaired control, social impairment, risky use, and pharmacological criteria. Emergency visits for cannabis-related issues are rising, particularly among 15-24 year-olds. Cannabinoid hyperemesis syndrome (CHS) causes severe nausea and vomiting, with cessation of cannabis use the only cure. No FDA-approved treatments exist for CUD, but clinical trials explore potential treatments like CBD, FAAH inhibitors, and N-acetylcysteine (NAC). Parental cannabis use influences teens' attitudes and intentions to use, highlighting the need for open conversations and clear boundaries.

Cumberland Pharmaceuticals' stock surged 96.77% after FDA approval of a simplified dosing regimen for Acetadote, an intravenous drug preventing liver injury from acetaminophen overdose. The new regimen aims to improve patient outcomes and reduce healthcare provider burden.

Cumberland Pharmaceuticals' stock surged over 90% today, up 101% in a month, driven by FDA approval of a supplementary New Drug Application for Acetadote®, simplifying dose schedules to improve safety and efficacy in treating liver damage from acetaminophen. Hospitals have adopted the strategy to reduce medication errors and severe non-allergic anaphylactoid responses. The FDA's Orphan Drug and Rare Pediatric Disease Designations for its Duchenne muscular dystrophy medication have also boosted investor confidence.

The FDA approved a simplified dosing regimen for N-acetylcysteine (NAC) to prevent liver injury from acetaminophen overdose, reducing medication errors and non-allergic anaphylactoid reactions (NAARs). Studies show the 2-bag regimen shortens delays and reduces NAARs compared to the 3-bag regimen, improving patient outcomes.

The FDA approved a simplified dosing regimen for Cumberland Pharmaceuticals Inc.'s Acetadote, aiming to prevent liver injury from acetaminophen poisoning by combining the first two bags of the standard regimen into a single, slower infusion to reduce medication errors and non-allergic anaphylactoid reactions.

Cumberland Pharmaceuticals announces FDA approval for a simplified dosing regimen of Acetadote, aiming to reduce medication errors and improve patient outcomes in treating acetaminophen poisoning.